SLC5A2 and diabetic kidney disease: Finally, a customized therapy consisting of two or three of the above-mentioned therapeutics (e.g., SGLT-2 inh.+GLP-1RA±finerenone) may appear as an effective therapeutic strategy for DKD; this, however, requires further investigations to aggregate evidence based knowledge in the field.